

Nexus SME Toolbox

Commercialising Regenerative Medicine

...issues we should have addressed earlier

Having spent the last 17 years commercialising several different RegenMed products which ranged from allogeneic 'skin substitutes' to autologous stem cell treatments; **Dr Michael Leek of Lab2Launch** has identified a number of occasions where product development and clinical progress were significantly delayed as a consequence of unforeseen issues.

With the benefit of hindsight, many of these issues could have been successfully addressed earlier – *'had we only known what they were...'*

In conjunction with



24 February 2010

Apex Hotel, Waterloo Place, Edinburgh

This event is free, however, places are limited.
To reserve your place, please complete an on-line
registration at www.nexxusscotland.com/events

nexus

Nexus SME Toolbox

Having spent the last 17 years commercialising several different RegenMed products which ranged from allogeneic ‘skin substitutes’ to autologous stem cell treatments; **Dr Michael Leek of Lab2Launch** has identified a number of occasions where product development and clinical progress were significantly delayed as a consequence of unforeseen issues.

With the benefit of hindsight, many of these issues could have been successfully addressed earlier – ‘*had we only known what they were...*’

Complications in the development process will be reviewed – these generally fall into one of the following six categories (with examples included):-

1. Regulatory
2. Quality
3. Manufacturing
4. Clinical
5. Logistics
6. Commercial

Programme

Registration / Sandwich Lunch

12.00 - 12.30pm

Commercialising Regenerative Medicine

12.30 - 1.30pm

Dr Michael D Leek, Vice President, Lab2Launch

Described by Prof. Chris Mason and Dr Stephen Minger (of the London Regenerative Medicine Network) as a ‘true pioneer in the field of Regenerative Medicine’, Michael was closely involved in establishing Smith and Nephew’s joint venture with Advanced Tissue Sciences (1994) which resulted in one of the first commercially available cell therapeutic products – DermaGraft.

Michael has extensive experience spanning many areas of regenerative medicine, and was recently employed as Vice-President of Operations for a company treating liver cirrhosis patients with an autologous infusion of stem cells (developed to initiate regeneration of new hepatic tissue).

Question and Answer / Networking

1.30 - 2.00pm



Nexus is currently funded by the European Regional Development Fund and a number of Scottish organisations - see website for full details

